Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy

Autor: Shingo Matsumoto, Gaku Nakazawa, Yohei Ohno, Mai Ishihara, Katsuaki Sakai, Norihito Nakamura, Tsutomu Murakami, Makoto Natsumeda, Takayuki Kabuki, Atsushi Shibata, Keisuke Kida, Masaaki Konishi, Shunsuke Ishii, Takanori Ikeda, Yuji Ikari
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: ESC Heart Failure, Vol 7, Iss 6, Pp 4172-4181 (2020)
Druh dokumentu: article
ISSN: 2055-5822
DOI: 10.1002/ehf2.13042
Popis: Abstract Aims Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relative to HF with reduced ejection fraction (HFrEF), although clinical features regarding circulating ANP in HFpEF and HFrEF have not been fully investigated during acute HF. Here, we characterized the differential regulation of circulating ANP and the efficacy of exogenous ANP (carperitide) in patients with acute HF, especially HFpEF. Methods and results Serum ANP levels before treatment and the diuretic effect of 0.0125 μg/kg/min of carperitide alone for the first 6 h were prospectively evaluated in 113 patients with acute HF who were divided into two groups: HFpEF vs. HFrEF. We mainly analysed the impact of baseline ANP levels and the presence of HFpEF on the diuretic effect of exogenous ANP. There was an inverse relationship between ANP levels and the diuretic effect of exogenous ANP (r2 = 0.19, P
Databáze: Directory of Open Access Journals